Genomic testing is a critical component of determining how to treat a patient that has been diagnosed with Non-Small Cell Lung Cancer (NSCLC). Since certain treatments are more effective in treating tumors with specific mutations, molecular profiling of tumors (genomic testing) is beneficial in determining the best options for therapy.

Genomic testing involves identifying biomarkers called “driver mutations.” With NSCLC, identifying the driver mutation and then matching the drug accordingly is shown to result in increased treatment efficacy. Therefore, genomic testing has become the standard initial procedure for a patient with NSCLC.

We are committed to pursuing and implementing new technologies which lead to better results for our patients. Our goal is to not only provide patients with cutting-edge oncology therapies but also compassionate and personalized care. If you have received a diagnosis of Non-Small Cell Lung Cancer and are interested in learning more about genomic testing, please call us to set up an appointment.

For more information about NSCLC and genomic testing, consider the following resources:

American Cancer Society

Memorial Sloan Kettering Cancer Center